Abstract
Models of infectious disease transmission have shown the importance of heterogeneous contact networks for epidemiology; the most connected individuals are most likely to be infected early. Yet it is cumbersome to parameterize and incorporate such networks into simple models. We introduce an alternative model framework that explicitly includes attendance at and disease transmission within gatherings of different sizes, which disaggregates sequential epidemics moving from the most to least social subpopulations that underly the overall, single-peaked infection curve. This can systematically bias initial estimates of the growth rate for emerging variants and their severity, if vulnerable populations avoid large gatherings. Finally, we show that how often similarly social individuals preferentially interact (i.e., homophily, or assortative mixing) tunes the magnitude and duration of these biases. Together, we provide a simple framework for incorporating socialization and behavior in epidemic models, which can help contextualize surveillance of emerging infectious agents.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project has been funded (in part) by contract 200-2016-91779 with the Centers for Disease Control and Prevention and by contract U01 CA261277 through SeroNet. Disclaimer: The findings, conclusions, and views expressed are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated text to increase readability in response to feedback.
Data Availability
All data produced are available online at https://github.com/bradfordptaylor/risk_sir
